Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2007 May 1;23(6):481-2; author reply 483.
doi: 10.1016/s0828-282x(07)70793-6.

Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

Kyle MacNair, Shawn Bugden; Canadian Academic Detailing Collaboration
Comment

Re: Canadian Cardiovascular Society position statement--recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease

Kyle MacNair et al. Can J Cardiol. .
No abstract available

PubMed Disclaimer

Figures

Figure 1)
Figure 1)
Average low-density lipoprotein cholesterol (LDL-C) reductions of HMG-CoA reductase inhibitors (16)
See this image and copyright information in PMC

Comment on

References

    1. Genest J, Frohlich J, Fodor G, McPherson R, Working Group on Hypercholesterolemia and Other Dyslipidemias Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: Summary of the 2003 update CMAJ 2003169921–4. (Erratum in 2003;169:1149). - PMC - PubMed
    1. The AGREE Collaboration Appraisal of Guidelines for Research and Evaluation Instrument September2001. <www.agreecollaboration.org/instrument> (Version current at March 22, 2007).
    1. Hindle HR. Dyslipidemia guidelines. CMAJ. 2004;171:118. - PMC - PubMed
    1. LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–35. - PubMed
    1. Pedersen TR, Faergeman O, Kastelein JJ, et al. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial JAMA 20052942437–45. (Erratum in 2005;294:3092). - PubMed